Research Topics
| Ross A AbramsSummaryAffiliation: Rush University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinomaRoss Allen Abrams
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612 3833, USA
Cancer J 18:624-32. 2012..Radiation Therapy Oncology Group trial 0848, currently accruing and ongoing, has been designed to clarify the role of radiotherapy in the adjuvant management of pancreatic cancer...- Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?Ross A Abrams
Department of Radiation Oncology, Rush University Medical Center, Atrium Bldg, Ground Floor, 500 S Paulina, Chicago, IL 60612, USA
Expert Rev Gastroenterol Hepatol 6:149-61. 2012..This review examines this controversy and the underlying issues and considers current efforts towards resolving them, as well as some likely future developments... 
Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal"Ross A Abrams
Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois 60612-3833, USA
Drugs 67:2481-5; discussion 2491-3. 2007- Radiotherapy in the adjuvant management of pancreatic adenocarcinomaRoss A Abrams
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Semin Oncol 32:S30-2. 2005..On balance, it is likely that optimal adjuvant therapy for pancreatic adenocarcinoma requires both radiotherapy and chemotherapy... - Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991-2003Ross A Abrams
Department of Radiation Oncology, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
Surg Oncol Clin N Am 13:621-38, ix. 2004.... 
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704Timothy N Showalter
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Int J Radiat Oncol Biol Phys 81:1328-35. 2011....- Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreasRoss A Abrams
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Int J Radiat Oncol Biol Phys 82:809-16. 2012..5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity... - Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patientsBenjamin T Gielda
Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois 60612, USA
J Thorac Oncol 6:1079-86. 2011..We reviewed our experience in advanced NSCLC since 1999. Subset analysis was performed on poor-risk patients... - Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survivalBenjamin T Gielda
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Int J Radiat Oncol Biol Phys 81:985-91. 2011..We reviewed a decade of single institution experience with preoperative split-course CRT followed by surgical resection to evaluate survival and identify factors that may be helpful in predicting outcome... - Evaluation of four volume-based image registration algorithmsYunkai Zhang
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA
Med Dosim 34:317-22. 2009..As for the robustness, NMI and BSMI outperformed CC and LC. A guideline of image registration in our institution was given, and final visual assessment is necessary to guarantee reasonable results... - Management of a patient with borderline resectable pancreatic cancer. Case report and reviewAnand P Shah
Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois 60612, USA
Oncology (Williston Park) 22:1524-9. 2008.... - Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancerAnand P Shah
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA
Am J Clin Oncol 33:101-6. 2010..Clearly, no combination of currently available agents is sufficient to provide acceptable cure rates in pancreatic cancer and novel therapies must be found... - Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialWilliam F Regine
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
JAMA 299:1019-26. 2008..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil... - Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settingsAdam Dickler
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612-3804, USA
Semin Radiat Oncol 15:235-44. 2005..The challenges of clinical research are well reflected by the controversies resulting from available studies and the difficulties in successfully designing and executing future trials... - Variation in post-surgical lumpectomy cavity volume with delay in initiation of breast irradiation because of chemotherapyJonathan B Strauss
Rush University Medical Center, Department of Radiation Oncology, Chicago, IL, USA
Int J Radiat Oncol Biol Phys 77:831-5. 2010..However, contraction of the lumpectomy cavity over time may have implications for the volume of tissue included in the boost field... - A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneityRui Yao
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Med Phys 39:2239-48. 2012..The purpose of this paper is to present and discuss the authors' TBI technique, which both simplifies the treatment process and improves the treatment quality... - Radiation therapy for heterotopic ossification prophylaxis afer high-risk elbow surgeryJonathan B Strauss
Northwestern Memorial Hospital, Chicago, Illinois 60611, USA
Am J Orthop (Belle Mead NJ) 40:400-5. 2011..Our findings support the idea that RT, in combination with NSAID use, is safe and efficacious in preventing development of clinically significant HO in the elbow... - Adjuvant therapy for pancreatic cancer: current status, future directionsWilliam F Regine
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore MD 21201, USA
Semin Oncol 33:S10-3. 2006..Just cause for optimism exists, but much work remains to be done. New adjuvant therapies need to be developed and tested, in carefully designed, well-executed, efficient clinical trials... - A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapyAdam Dickler
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Brachytherapy 6:164-8. 2007..This analysis was undertaken to dosimetrically compare the results of treatment using these two methods of PBI... - Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and ApproachesJames C Marsh
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
J Oncol 2010:198208. 2010..This review discusses these concepts in detail as well as providing both neuroanatomic and radiobiologic background relevant to these issues... - Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patientsJames C Marsh
Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois, USA
Int J Radiat Oncol Biol Phys 76:504-12. 2010..This review was performed to assess the feasibility of selectively sparing the limbic system during whole-brain radiotherapy and prophylactic cranial irradiation... - Application of holographic display in radiotherapy treatment planning II: a multi-institutional studyJames Ch Chu
Rush University Medical Center, Chicago, IL, USA
J Appl Clin Med Phys 10:2902. 2009..These data indicate that continued development of this technology for clinical implementation is warranted... - Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51Thomas B Daniels
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 81:218-24. 2011..We sought to independently validate this prognostic index with a separate prospectively collected data set (Intergroup 86-72-51)... - Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlasRobert J Myerson
Department of Radiation Oncology, Washington University, St Louis, MO, USA
Int J Radiat Oncol Biol Phys 74:824-30. 2009..To develop a Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers... - Assessment of pancreatic cancer care in the United States based on formally developed quality indicatorsKarl Y Bilimoria
Cancer Programs, American College of Surgeons, 633 N St Clair St, Chicago, IL 60611, USA
J Natl Cancer Inst 101:848-59. 2009..However, valid quality indicators are not currently available for pancreatic cancer management, and a composite assessment of the quality of pancreatic cancer care in the United States has not been done... - Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitisThomas Liggett
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
Cancer 116:1674-80. 2010..In this article, the authors describe a methylation profile of cell-free plasma DNA that distinguished CP from PanCa with >90% accuracy... - Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trialsChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 56:31-7. 2003..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer... - Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)Atif J Khan
Department of Radiation Oncology, Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Radiother Oncol 81:163-7. 2006..This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease... - A feasibility study of Dynamic Phantom scanner for quality assurance of photon beam profiles at various gantry anglesYunkai Zhang
Department of Medical Physics, Rush University Medical Center, 1653 West Congress Parkway, Chicago, Illinois 60612, USA
J Appl Clin Med Phys 6:50-61. 2005..Caution should be taken when using this device to acquire basic electron dosimetry data... - Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivorsTom C Nguyen
Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-4606, USA
J Gastrointest Surg 7:1-9; discussion 9-11. 2003..These results imply that no negative long-term QOL measures are associated with radical pancreaticoduodenectomy (as performed in this study) for periampullary adenocarcinoma... - Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?Ross A Abrams
Division of Radiation Oncology, Kimmel Cancer Center, Johns Hopkins University and Johns Hopkins Hospital, Baltimore, MD 21231, USA
Int J Radiat Oncol Biol Phys 56:3-9. 2003.... - Pancreatic cancerTheresa Pluth Yeo
Departments of Surgery, Oncology, Pathology and Medicine Johns Hopkins Medical Institutions Baltimore, Maryland, USA
Curr Probl Cancer 26:176-275. 2002 - Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survivalTaylor S Riall
Departments of Surgery, The Sol Goldman Pancreas Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Gastrointest Surg 9:1191-204; discussion 1204-6. 2005..002)... - A challenge to the therapeutic nihilism of ESPAC-1Mary C Koshy
Int J Radiat Oncol Biol Phys 61:965-6. 2005 - Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II studyDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
J Clin Oncol 23:4991-8. 2005.... - Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile ductMichael A Hughes
Therapeutic Radiologists, Inc, Kansas City, MO, USA
Int J Radiat Oncol Biol Phys 68:178-82. 2007..To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival... - Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortalityCharles J Yeo
Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Ann Surg 236:355-66; discussion 366-8. 2002..To evaluate, in a prospective, randomized single-institution trial, the end points of operative morbidity, operative mortality, and survival in patients undergoing standard versus radical (extended) pancreaticoduodenectomy... - Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphomaYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 11:39-46. 2005..Whether allogeneic BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined... - High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvementYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 11:93-100. 2005..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated... - Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenumMichael J Swartz
Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, MD 21231, USA
Arch Surg 142:285-8. 2007..Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy...